Antisense & RNAi Therapeutics Market – Global Industry Analysis and Forecasts (2024– 2030)


Antisense and RNAi Therapeutics Market was valued at US$ 1.63 Bn. in 2023 and is expected to reach US$ 3.38 Bn. by 2030, at a CAGR of 11% during the forecast period of 2024 to 2030.

Antisense and RNAi Therapeutics Market Overview 

In past years, pharmaceutical companies were motivated about the prospective of RNA interference (RNAi). But later, financial volatility and subsequent suspensions by pharmaceutical companies have articulated that the RNAi therapeutics market was finished. Yet, advances in nanomedicine helped the vast potential of RNAi therapeutics to flourish. Antisense technology offers the prospect to influence gene expression and this is being considered as an effective treatment for various diseases. Based on this factor, a great number of gene silencing drugs are in the development process.Antisense & RNAi Therapeutics MarketTo know about the Research Methodology:- Request Free Sample Report

The report study has analyzed the revenue impact of a covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and the same is reflected in our analysis.

The global antisense and RNAi therapeutics market have gathered substantial attention in recent years, due to its perspective to treat any sort of chronic diseases such as tuberculosis, diabetes, cancer, AIDS, as well as certain cardiovascular problems.  This prospect is being cashed on by the many companies in this industry and is investing in R&D. Just to emerge as being in the clinical research division, the RNA-based therapeutics are likely to be explored as a most efficient treatment choice for the disorders, which are very difficult to treat. The market is expected to grow at CAGR XX.XX % over the forecast period, the number of companies are into the development of molecules focused on antisense technology.

However, there are many challenges associated with the emerging antisense technology and RNAi. One of the noticeable issues is the drug delivery to the proposed portion. Drug delivery to the nervous tissues is one of the problems as the drug has to pass the blood-brain barrier. Major players in the industry are coming up with solutions to overcome these challenges.

The other challenge is the toxic effects caused by the use of this technology. Determining the right dosage and path for drug delivery of an antisense molecule is one of the most crucial processes to ensure safe administration. While overcoming this as much as possible and implementing it, companies have encountered multiple rejections from the regulatory bodies. For instance, FDA has refused, an antisense molecule to treat familial chylomicronemia syndrome by the renowned U.S. organization Akcea’s Waylivra. Such events would push companies to develop better paths, efficient delivery solutions, and effective compositions.

Antisense and RNAi Therapeutics Market Growth Factors

In RNAi therapeutics, more influential product focus vs. platform technologies and virtual drug expansion models that enable several companies to minimize the R&D costs, are expected to attract investors and supplement the growth of the market. Instead, major issues in drug delivery, as well as high failure rates, are some of the biggest barriers for companies working in this particular field. Despite the limitations, the players in the pharmaceutical sector are interested and focused on the commercialization of these therapies, hence the antisense and RNAi therapeutics market have the chances to grow substantially with the CAGR of XX.XX % and expected to reach US$ XX.XX Mn by the end of the forecast period.

Antisense and RNAi Therapeutics Market Segment Analysis

The global antisense and RNAi therapeutics market is classified into technology, application, and route of administration. In terms of technology, the global antisense and RNAi therapeutics market is bifurcated into RNA interference and antisense RNA. The segment of RNA interference is further sub-divided into miRNA and siRNA.

In terms of application, the global antisense and RNAi therapeutics market are categorized into cardiovascular, oncology, renal diseases, respiratory disorder, genetic disorders, neurodegenerative disorder, infectious diseases, and others. In terms of route of administration, the global antisense and RNAi therapeutics market is sub-segmented into intravenous injections, pulmonary delivery, intraperitoneal injections, intradermal Injections, topical delivery, and other delivery methods.

Antisense and RNAi Therapeutics Market Regional Analysis

North America has experienced being the most lucrative market in recent times and has contributed a substantial share in the Global Antisense and RNAi Therapeutics Market. Multiple clinical trials have shown favourable results and are even progressing through the development stages. Supposing such trials expected to show positive results, the North American market can be expected to witness exponential growth during the forecast period. Furthermore, in the U.S. several biotechnology companies have made considerably high investments for RNAi therapeutic development and a number of RNAi therapeutics are in the final stage of development phases.

In North America, clinical laboratories are likely to contribute significant revenue generation via platform and product licensing. Supportive government regulation and provision to increase the number of clinical trials therein encourages the method of initiation for exploring antisense therapeutics. The forthcoming commercialization of several players are under R&D will help to boost the global antisense and RNAi therapeutics market in North America in the forecast period.

The increasing government expenditure toward R&D, as well as different forms of siRNA delivery methods, is a strong side propelling the growth of the global antisense and RNAi therapeutics market in the Asia Pacific region. Still, this region is experiencing a moderate growth rate with a CAGR of XX.XX % during 2015-2019, but post commercialization of these therapies, prospects, and forthcoming opportunities in the Asia Pacific are likely to be more profitable, presenting a maximum development rate with the consistently growing CAGR of XX.XX % in the forecast period from 2024 to 2030.

Antisense and RNAi Therapeutics Market Insights and developments

In recent years there are many discoveries in the field of technologies with regard to the Global Antisense & RNAi Therapeutics Market, which in turn will help the industry to grow. Big pharmaceutical developers have entered into collaboration agreements or outsourcing deals with several smaller firms & new entrants in an effort to take advantage of the expected growth in revenue that this market can generate over the forecast period. For instance, the Agreement between AstraZeneca’s and Ionis pharmaceuticals is one of the big deals that are hugely investing & doing R&D into antisense technology.

Since the discovery of RNAi, there are various ways of treatment of multiple diseases using RNAi, still, the market has picked up very little over the past decade due to the complexities in delivery methodologies associated with RNAi. But due to initiatives by key players and ongoing R&D have shown the chances of better growth.

The rising need for the cure and prevention of diseases like cancer, AIDS and several diseases caused by mutating viruses is anticipated to impact the usage rate of oligonucleotide products. This field is rapidly expanding owing to the increasing number of clinical trials for oligonucleotide drugs. For instance, Ionis Pharmaceuticals has 2 approved molecules in the European Union and 1 in the U.S. along with 4 molecules in the pipeline.

Many key players are putting efforts into developing novel delivery systems like nanocarriers, to encourage the in-vivo delivery of the oligonucleotides. To develop the bioavailability, the carrying capability of siRNA payload and the deliver high interface with the target cells are the key functions of Nanocarriers, for which they are recognized mostly. The development of newer nanotechnology-oriented methods has offered a high potential to the market to grow during the forecast period.

Nanocarriers can reduce the toxicity of these oligonucleotides. There is a huge need for the latest and harmless delivery systems for cancer and other viral diseases, which is expected to supplement the market growth. Significant pipeline for cancer therapies by organizations and institutes such as Enzon Pharmaceuticals (Santaris Pharma), OncoGenex, University of Texas, Astrazeneca (Ionis Pharmaceuticals), Isarna Therapeutics and INSYS Therapeutics, Inc. have a huge contribution in driving the market.

Detailed analysis of competition, new entrants, strategic alliances, mergers and acquisition in the Global Antisense & RNAi Therapeutics Market is covered in the report.  The report covers the market leaders and followers in the industry with the market dynamics by region. It will also help to understand the position of each player in the market by region, by segment.

 Antisense and RNAi Therapeutics Market Scope: Inquire before buying






Antisense and RNAi Therapeutics Market




Report Coverage
Details




Base Year:
2023
Forecast Period:
2024-2030




Historical Data:
2018 to 2023
Market Size in 2023:
US $ 1.63 Bn.




Forecast Period 2024 to 2030 CAGR:
11%
Market Size in 2030:
US $ 3.38 Bn.




 Segments Covered:
by Technology
RNA Interference
siRNA
miRNA
Antisense RNA




by Application
Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Renal Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other




by Administration
Pulmonary Delivery
Intravenous Injections
Intra-dermal Injections
Intraperitoneal Injections
Topical Delivery
Other Delivery Methods






Antisense and RNAi Therapeutics Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (razil, Argentina Rest of South America)

Antisense & RNAi Therapeutics Market Key Players:

1 GSK,
2 Sanofi-Genzyme,
3 Alnylam Pharmaceuticals,
4 Marina Biosciences,
5 Benitec Biopharma,
6 Alnylam Pharmaceuticals,
7 Ionis Pharmaceuticals,
8 Akcea Therapeutics,
9 Quark Pharmaceuticals,
10 Gene Signal
11 Astellas Pharma Inc
12 Dicerna Pharmaceuticals
13 Tekmira Pharmaceuticals
14 Benitec Biopharma
15 Silence Therapeutics
16 Cenix BioScience
17 Sirnaomics
18 CureVac AG

Frequently Asked Questions:

1. Which region has the largest share in Market?
Ans: North America region held the highest share in 2023.

2. What is the growth rate of Market?
Ans: The Global Antisense and RNAi Therapeutics Market is growing at a CAGR of 11 % during forecasting period 2024-2030.

3. What is scope of the market report?
Ans: Global Antisense and RNAi Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. What is the study period of this market?
Ans: The Global Antisense and RNAi Therapeutics Market is studied from 2023 to 2030. 





Antisense & RNAi Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Antisense & RNAi Therapeutics Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Antisense & RNAi Therapeutics Market Analysis and Forecast
6.1. Antisense & RNAi Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Antisense & RNAi Therapeutics Market Analysis and Forecast, by Technology
7.1. Introduction and Definition
7.2. Key Findings
7.3. Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
7.4. Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Technology
7.5. Antisense & RNAi Therapeutics Market Analysis, by Technology
7.6. Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Technology

8. Antisense & RNAi Therapeutics Market Analysis and Forecast, by Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
8.4. Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Application
8.5. Antisense & RNAi Therapeutics Market Analysis, by Application
8.6. Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Application

9. Antisense & RNAi Therapeutics Market Analysis and Forecast, by Route of Administration
9.1. Introduction and Definition
9.2. Key Findings
9.3. Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
9.4. Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration
9.5. Antisense & RNAi Therapeutics Market Analysis, by Route of Administration
9.6. Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Route of Administration

10. Antisense & RNAi Therapeutics Market Analysis, by Region
10.1. Antisense & RNAi Therapeutics Market Value Share Analysis, by Region
10.2. Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Region
10.3. Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Region

11. North America Antisense & RNAi Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Antisense & RNAi Therapeutics Market Overview
11.3. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
11.4. North America Antisense & RNAi Therapeutics Market Forecast, by Technology
11.4.1. RNA Interference
11.4.1.1. siRNA
11.4.1.2. miRNA
11.4.2. Antisense RNA
11.5. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
11.6. North America Antisense & RNAi Therapeutics Market Forecast, by Application
11.6.1. Oncology
11.6.2. Cardiovascular Diseases (CVDs)
11.6.3. Respiratory Disorders
11.6.4. Renal Diseases
11.6.5. Neurodegenerative Disorders
11.6.6. Genetic Disorders
11.6.7. Infectious Diseases
11.6.8. Other
11.7. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
11.8. North America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
11.8.1. Pulmonary Delivery
11.8.2. Intravenous Injections
11.8.3. Intra-dermal Injections
11.8.4. Intraperitoneal Injections
11.8.5. Topical Delivery
11.8.6. Other Delivery Methods
11.9. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Country
11.10. North America Antisense & RNAi Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Antisense & RNAi Therapeutics Market Analysis, by Country
11.12. U.S. Antisense & RNAi Therapeutics Market Forecast, by Technology
11.12.1. RNA Interference
11.12.1.1. siRNA
11.12.1.2. miRNA
11.12.2. Antisense RNA
11.13. U.S. Antisense & RNAi Therapeutics Market Forecast, by Application
11.13.1. Oncology
11.13.2. Cardiovascular Diseases (CVDs)
11.13.3. Respiratory Disorders
11.13.4. Renal Diseases
11.13.5. Neurodegenerative Disorders
11.13.6. Genetic Disorders
11.13.7. Infectious Diseases
11.13.8. Other
11.14. U.S. Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
11.14.1. Pulmonary Delivery
11.14.2. Intravenous Injections
11.14.3. Intra-dermal Injections
11.14.4. Intraperitoneal Injections
11.14.5. Topical Delivery
11.14.6. Other Delivery Methods
11.15. Canada Antisense & RNAi Therapeutics Market Forecast, by Technology
11.15.1. RNA Interference
11.15.1.1. siRNA
11.15.1.2. miRNA
11.15.2. Antisense RNA
11.16. Steel Canada Antisense & RNAi Therapeutics Market Forecast, by Application
11.16.1. Oncology
11.16.2. Cardiovascular Diseases (CVDs)
11.16.3. Respiratory Disorders
11.16.4. Renal Diseases
11.16.5. Neurodegenerative Disorders
11.16.6. Genetic Disorders
11.16.7. Infectious Diseases
11.16.8. Other
11.17. Canada Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
11.17.1. Pulmonary Delivery
11.17.2. Intravenous Injections
11.17.3. Intra-dermal Injections
11.17.4. Intraperitoneal Injections
11.17.5. Topical Delivery
11.17.6. Other Delivery Methods
11.18. North America Antisense & RNAi Therapeutics Market Attractiveness Analysis
11.18.1. By Technology
11.18.2. By Application
11.18.3. By Route of Administration
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Antisense & RNAi Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Antisense & RNAi Therapeutics Market Overview
12.3. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
12.4. Europe Antisense & RNAi Therapeutics Market Forecast, by Technology
12.4.1. RNA Interference
12.4.1.1. siRNA
12.4.1.2. miRNA
12.4.2. Antisense RNA
12.5. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
12.6. Europe Antisense & RNAi Therapeutics Market Forecast, by Application
12.6.1. Oncology
12.6.2. Cardiovascular Diseases (CVDs)
12.6.3. Respiratory Disorders
12.6.4. Renal Diseases
12.6.5. Neurodegenerative Disorders
12.6.6. Genetic Disorders
12.6.7. Infectious Diseases
12.6.8. Other
12.7. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
12.8. Europe Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.8.1. Pulmonary Delivery
12.8.2. Intravenous Injections
12.8.3. Intra-dermal Injections
12.8.4. Intraperitoneal Injections
12.8.5. Topical Delivery
12.8.6. Other Delivery Methods
12.9. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Country
12.10. Europe Antisense & RNAi Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Antisense & RNAi Therapeutics Market Analysis, by Country
12.12. Germany Antisense & RNAi Therapeutics Market Forecast, by Technology
12.12.1. RNA Interference
12.12.1.1. siRNA
12.12.1.2. miRNA
12.12.2. Antisense RNA
12.13. Germany Antisense & RNAi Therapeutics Market Forecast, by Application
12.13.1. Oncology
12.13.2. Cardiovascular Diseases (CVDs)
12.13.3. Respiratory Disorders
12.13.4. Renal Diseases
12.13.5. Neurodegenerative Disorders
12.13.6. Genetic Disorders
12.13.7. Infectious Diseases
12.13.8. Other
12.14. Germany Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.14.1. Pulmonary Delivery
12.14.2. Intravenous Injections
12.14.3. Intra-dermal Injections
12.14.4. Intraperitoneal Injections
12.14.5. Topical Delivery
12.14.6. Other Delivery Methods
12.15. U.K. Antisense & RNAi Therapeutics Market Forecast, by Technology
12.15.1. RNA Interference
12.15.1.1. siRNA
12.15.1.2. miRNA
12.15.2. Antisense RNA
12.16. U.K. Antisense & RNAi Therapeutics Market Forecast, by Application
12.16.1. Oncology
12.16.2. Cardiovascular Diseases (CVDs)
12.16.3. Respiratory Disorders
12.16.4. Renal Diseases
12.16.5. Neurodegenerative Disorders
12.16.6. Genetic Disorders
12.16.7. Infectious Diseases
12.16.8. Other
12.17. U.K. Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.17.1. Pulmonary Delivery
12.17.2. Intravenous Injections
12.17.3. Intra-dermal Injections
12.17.4. Intraperitoneal Injections
12.17.5. Topical Delivery
12.17.6. Other Delivery Methods
12.18. France Antisense & RNAi Therapeutics Market Forecast, by Technology
12.18.1. RNA Interference
12.18.1.1. siRNA
12.18.1.2. miRNA
12.18.2. Antisense RNA
12.19. France Antisense & RNAi Therapeutics Market Forecast, by Application
12.19.1. Oncology
12.19.2. Cardiovascular Diseases (CVDs)
12.19.3. Respiratory Disorders
12.19.4. Renal Diseases
12.19.5. Neurodegenerative Disorders
12.19.6. Genetic Disorders
12.19.7. Infectious Diseases
12.19.8. Other
12.20. France Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.20.1. Pulmonary Delivery
12.20.2. Intravenous Injections
12.20.3. Intra-dermal Injections
12.20.4. Intraperitoneal Injections
12.20.5. Topical Delivery
12.20.6. Other Delivery Methods
12.21. Italy Antisense & RNAi Therapeutics Market Forecast, by Technology
12.21.1. RNA Interference
12.21.1.1. siRNA
12.21.1.2. miRNA
12.21.2. Antisense RNA
12.22. Italy Antisense & RNAi Therapeutics Market Forecast, by Application
12.22.1. Oncology
12.22.2. Cardiovascular Diseases (CVDs)
12.22.3. Respiratory Disorders
12.22.4. Renal Diseases
12.22.5. Neurodegenerative Disorders
12.22.6. Genetic Disorders
12.22.7. Infectious Diseases
12.22.8. Other
12.23. Italy Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.23.1. Pulmonary Delivery
12.23.2. Intravenous Injections
12.23.3. Intra-dermal Injections
12.23.4. Intraperitoneal Injections
12.23.5. Topical Delivery
12.23.6. Other Delivery Methods
12.24. Spain Antisense & RNAi Therapeutics Market Forecast, by Technology
12.24.1. RNA Interference
12.24.1.1. siRNA
12.24.1.2. miRNA
12.24.2. Antisense RNA
12.25. Spain Antisense & RNAi Therapeutics Market Forecast, by Application
12.25.1. Oncology
12.25.2. Cardiovascular Diseases (CVDs)
12.25.3. Respiratory Disorders
12.25.4. Renal Diseases
12.25.5. Neurodegenerative Disorders
12.25.6. Genetic Disorders
12.25.7. Infectious Diseases
12.25.8. Other
12.26. Spain Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.26.1. Pulmonary Delivery
12.26.2. Intravenous Injections
12.26.3. Intra-dermal Injections
12.26.4. Intraperitoneal Injections
12.26.5. Topical Delivery
12.26.6. Other Delivery Methods
12.27. Rest of Europe Antisense & RNAi Therapeutics Market Forecast, by Technology
12.27.1. RNA Interference
12.27.1.1. siRNA
12.27.1.2. miRNA
12.27.2. Antisense RNA
12.28. Rest of Europe Antisense & RNAi Therapeutics Market Forecast, by Application
12.28.1. Oncology
12.28.2. Cardiovascular Diseases (CVDs)
12.28.3. Respiratory Disorders
12.28.4. Renal Diseases
12.28.5. Neurodegenerative Disorders
12.28.6. Genetic Disorders
12.28.7. Infectious Diseases
12.28.8. Other
12.29. Rest Of Europe Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
12.29.1. Pulmonary Delivery
12.29.2. Intravenous Injections
12.29.3. Intra-dermal Injections
12.29.4. Intraperitoneal Injections
12.29.5. Topical Delivery
12.29.6. Other Delivery Methods
12.30. Europe Antisense & RNAi Therapeutics Market Attractiveness Analysis
12.30.1. By Technology
12.30.2. By Application
12.30.3. By Route of Administration
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Antisense & RNAi Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Antisense & RNAi Therapeutics Market Overview
13.3. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
13.4. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Technology
13.4.1. RNA Interference
13.4.1.1. siRNA
13.4.1.2. miRNA
13.4.2. Antisense RNA
13.5. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
13.6. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Application
13.6.1. Oncology
13.6.2. Cardiovascular Diseases (CVDs)
13.6.3. Respiratory Disorders
13.6.4. Renal Diseases
13.6.5. Neurodegenerative Disorders
13.6.6. Genetic Disorders
13.6.7. Infectious Diseases
13.6.8. Other
13.7. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
13.8. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.8.1. Pulmonary Delivery
13.8.2. Intravenous Injections
13.8.3. Intra-dermal Injections
13.8.4. Intraperitoneal Injections
13.8.5. Topical Delivery
13.8.6. Other Delivery Methods
13.9. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Antisense & RNAi Therapeutics Market Analysis, by Country
13.12. China Antisense & RNAi Therapeutics Market Forecast, by Technology
13.12.1. RNA Interference
13.12.1.1. siRNA
13.12.1.2. miRNA
13.12.2. Antisense RNA
13.13. China Antisense & RNAi Therapeutics Market Forecast, by Application
13.13.1. Oncology
13.13.2. Cardiovascular Diseases (CVDs)
13.13.3. Respiratory Disorders
13.13.4. Renal Diseases
13.13.5. Neurodegenerative Disorders
13.13.6. Genetic Disorders
13.13.7. Infectious Diseases
13.13.8. Other
13.14. China Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.14.1. Pulmonary Delivery
13.14.2. Intravenous Injections
13.14.3. Intra-dermal Injections
13.14.4. Intraperitoneal Injections
13.14.5. Topical Delivery
13.14.6. Other Delivery Methods
13.15. India Antisense & RNAi Therapeutics Market Forecast, by Technology
13.15.1. RNA Interference
13.15.1.1. siRNA
13.15.1.2. miRNA
13.15.2. Antisense RNA
13.16. India Antisense & RNAi Therapeutics Market Forecast, by Application
13.16.1. Oncology
13.16.2. Cardiovascular Diseases (CVDs)
13.16.3. Respiratory Disorders
13.16.4. Renal Diseases
13.16.5. Neurodegenerative Disorders
13.16.6. Genetic Disorders
13.16.7. Infectious Diseases
13.16.8. Other
13.17. India Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.17.1. Pulmonary Delivery
13.17.2. Intravenous Injections
13.17.3. Intra-dermal Injections
13.17.4. Intraperitoneal Injections
13.17.5. Topical Delivery
13.17.6. Other Delivery Methods
13.18. Japan Antisense & RNAi Therapeutics Market Forecast, by Technology
13.18.1. RNA Interference
13.18.1.1. siRNA
13.18.1.2. miRNA
13.18.2. Antisense RNA
13.19. Japan Antisense & RNAi Therapeutics Market Forecast, by Application
13.19.1. Oncology
13.19.2. Cardiovascular Diseases (CVDs)
13.19.3. Respiratory Disorders
13.19.4. Renal Diseases
13.19.5. Neurodegenerative Disorders
13.19.6. Genetic Disorders
13.19.7. Infectious Diseases
13.19.8. Other
13.20. Japan Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.20.1. Pulmonary Delivery
13.20.2. Intravenous Injections
13.20.3. Intra-dermal Injections
13.20.4. Intraperitoneal Injections
13.20.5. Topical Delivery
13.20.6. Other Delivery Methods
13.21. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Technology
13.21.1. RNA Interference
13.21.1.1. siRNA
13.21.1.2. miRNA
13.21.2. Antisense RNA
13.22. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Application
13.22.1. Oncology
13.22.2. Cardiovascular Diseases (CVDs)
13.22.3. Respiratory Disorders
13.22.4. Renal Diseases
13.22.5. Neurodegenerative Disorders
13.22.6. Genetic Disorders
13.22.7. Infectious Diseases
13.22.8. Other
13.23. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.23.1. Pulmonary Delivery
13.23.2. Intravenous Injections
13.23.3. Intra-dermal Injections
13.23.4. Intraperitoneal Injections
13.23.5. Topical Delivery
13.23.6. Other Delivery Methods
13.24. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Technology
13.24.1. RNA Interference
13.24.1.1. siRNA
13.24.1.2. miRNA
13.24.2. Antisense RNA
13.25. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Application
13.25.1. Oncology
13.25.2. Cardiovascular Diseases (CVDs)
13.25.3. Respiratory Disorders
13.25.4. Renal Diseases
13.25.5. Neurodegenerative Disorders
13.25.6. Genetic Disorders
13.25.7. Infectious Diseases
13.25.8. Other
13.26. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
13.26.1. Pulmonary Delivery
13.26.2. Intravenous Injections
13.26.3. Intra-dermal Injections
13.26.4. Intraperitoneal Injections
13.26.5. Topical Delivery
13.26.6. Other Delivery Methods
13.27. Asia Pacific Antisense & RNAi Therapeutics Market Attractiveness Analysis
13.27.1. By Technology
13.27.2. By Application
13.27.3. By Route of Administration
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Antisense & RNAi Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Antisense & RNAi Therapeutics Market Overview
14.3. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
14.4. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Technology
14.4.1. RNA Interference
14.4.1.1. siRNA
14.4.1.2. miRNA
14.4.2. Antisense RNA
14.5. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
14.6. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Application
14.6.1. Oncology
14.6.2. Cardiovascular Diseases (CVDs)
14.6.3. Respiratory Disorders
14.6.4. Renal Diseases
14.6.5. Neurodegenerative Disorders
14.6.6. Genetic Disorders
14.6.7. Infectious Diseases
14.6.8. Other
14.7. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
14.8. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
14.8.1. Pulmonary Delivery
14.8.2. Intravenous Injections
14.8.3. Intra-dermal Injections
14.8.4. Intraperitoneal Injections
14.8.5. Topical Delivery
14.8.6. Other Delivery Methods
14.9. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Antisense & RNAi Therapeutics Market Analysis, by Country
14.12. GCC Antisense & RNAi Therapeutics Market Forecast, by Technology
14.12.1. RNA Interference
14.12.1.1. siRNA
14.12.1.2. miRNA
14.12.2. Antisense RNA
14.13. GCC Antisense & RNAi Therapeutics Market Forecast, by Application
14.13.1. Oncology
14.13.2. Cardiovascular Diseases (CVDs)
14.13.3. Respiratory Disorders
14.13.4. Renal Diseases
14.13.5. Neurodegenerative Disorders
14.13.6. Genetic Disorders
14.13.7. Infectious Diseases
14.13.8. Other
14.14. GCC Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
14.14.1. Pulmonary Delivery
14.14.2. Intravenous Injections
14.14.3. Intra-dermal Injections
14.14.4. Intraperitoneal Injections
14.14.5. Topical Delivery
14.14.6. Other Delivery Methods
14.15. South Africa Antisense & RNAi Therapeutics Market Forecast, by Technology
14.15.1. RNA Interference
14.15.1.1. siRNA
14.15.1.2. miRNA
14.15.2. Antisense RNA
14.16. South Africa Antisense & RNAi Therapeutics Market Forecast, by Application
14.16.1. Oncology
14.16.2. Cardiovascular Diseases (CVDs)
14.16.3. Respiratory Disorders
14.16.4. Renal Diseases
14.16.5. Neurodegenerative Disorders
14.16.6. Genetic Disorders
14.16.7. Infectious Diseases
14.16.8. Other
14.17. South Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
14.17.1. Pulmonary Delivery
14.17.2. Intravenous Injections
14.17.3. Intra-dermal Injections
14.17.4. Intraperitoneal Injections
14.17.5. Topical Delivery
14.17.6. Other Delivery Methods
14.18. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Technology
14.18.1. RNA Interference
14.18.1.1. siRNA
14.18.1.2. miRNA
14.18.2. Antisense RNA
14.19. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Application
14.19.1. Oncology
14.19.2. Cardiovascular Diseases (CVDs)
14.19.3. Respiratory Disorders
14.19.4. Renal Diseases
14.19.5. Neurodegenerative Disorders
14.19.6. Genetic Disorders
14.19.7. Infectious Diseases
14.19.8. Other
14.20. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
14.20.1. Pulmonary Delivery
14.20.2. Intravenous Injections
14.20.3. Intra-dermal Injections
14.20.4. Intraperitoneal Injections
14.20.5. Topical Delivery
14.20.6. Other Delivery Methods
14.21. Middle East & Africa Antisense & RNAi Therapeutics Market Attractiveness Analysis
14.21.1. By Technology
14.21.2. By Application
14.21.3. By Route of Administration
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Antisense & RNAi Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Antisense & RNAi Therapeutics Market Overview
15.3. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology
15.4. South America Antisense & RNAi Therapeutics Market Forecast, by Technology
15.4.1. RNA Interference
15.4.1.1. siRNA
15.4.1.2. miRNA
15.4.2. Antisense RNA
15.5. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Application
15.6. South America Antisense & RNAi Therapeutics Market Forecast, by Application
15.6.1. Oncology
15.6.2. Cardiovascular Diseases (CVDs)
15.6.3. Respiratory Disorders
15.6.4. Renal Diseases
15.6.5. Neurodegenerative Disorders
15.6.6. Genetic Disorders
15.6.7. Infectious Diseases
15.6.8. Other
15.7. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration
15.8. South America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
15.8.1. Pulmonary Delivery
15.8.2. Intravenous Injections
15.8.3. Intra-dermal Injections
15.8.4. Intraperitoneal Injections
15.8.5. Topical Delivery
15.8.6. Other Delivery Methods
15.9. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Country
15.10. South America Antisense & RNAi Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Antisense & RNAi Therapeutics Market Analysis, by Country
15.12. Brazil Antisense & RNAi Therapeutics Market Forecast, by Technology
15.12.1. RNA Interference
15.12.1.1. siRNA
15.12.1.2. miRNA
15.12.2. Antisense RNA
15.13. Brazil Antisense & RNAi Therapeutics Market Forecast, by Application
15.13.1. Oncology
15.13.2. Cardiovascular Diseases (CVDs)
15.13.3. Respiratory Disorders
15.13.4. Renal Diseases
15.13.5. Neurodegenerative Disorders
15.13.6. Genetic Disorders
15.13.7. Infectious Diseases
15.13.8. Other
15.14. Brazil Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
15.14.1. Pulmonary Delivery
15.14.2. Intravenous Injections
15.14.3. Intra-dermal Injections
15.14.4. Intraperitoneal Injections
15.14.5. Topical Delivery
15.14.6. Other Delivery Methods
15.15. Mexico Antisense & RNAi Therapeutics Market Forecast, by Technology
15.15.1. RNA Interference
15.15.1.1. siRNA
15.15.1.2. miRNA
15.15.2. Antisense RNA
15.16. Mexico Antisense & RNAi Therapeutics Market Forecast, by Application
15.16.1. Oncology
15.16.2. Cardiovascular Diseases (CVDs)
15.16.3. Respiratory Disorders
15.16.4. Renal Diseases
15.16.5. Neurodegenerative Disorders
15.16.6. Genetic Disorders
15.16.7. Infectious Diseases
15.16.8. Other
15.17. Mexico Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
15.17.1. Pulmonary Delivery
15.17.2. Intravenous Injections
15.17.3. Intra-dermal Injections
15.17.4. Intraperitoneal Injections
15.17.5. Topical Delivery
15.17.6. Other Delivery Methods
15.18. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Technology
15.18.1. RNA Interference
15.18.1.1. siRNA
15.18.1.2. miRNA
15.18.2. Antisense RNA
15.19. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Application
15.19.1. Oncology
15.19.2. Cardiovascular Diseases (CVDs)
15.19.3. Respiratory Disorders
15.19.4. Renal Diseases
15.19.5. Neurodegenerative Disorders
15.19.6. Genetic Disorders
15.19.7. Infectious Diseases
15.19.8. Other
15.20. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration
15.20.1. Pulmonary Delivery
15.20.2. Intravenous Injections
15.20.3. Intra-dermal Injections
15.20.4. Intraperitoneal Injections
15.20.5. Topical Delivery
15.20.6. Other Delivery Methods
15.21. South America Antisense & RNAi Therapeutics Market Attractiveness Analysis
15.21.1. By Technology
15.21.2. By Application
15.21.3. By Route of Administration
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Alnylam Pharmaceuticals,
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. GSK,
16.3.3. Sanofi-Genzyme,
16.3.4. Marina Biosciences,
16.3.5. Benitec Biopharma,
16.3.6. Alnylam Pharmaceuticals,
16.3.7. Ionis Pharmaceuticals,
16.3.8. Akcea Therapeutics,
16.3.9. Quark Pharmaceuticals,
16.3.10. Gene Signal
16.3.11. Astellas Pharma Inc
16.3.12. Dicerna Pharmaceuticals
16.3.13. Tekmira Pharmaceuticals
16.3.14. Benitec Biopharma
16.3.15. Silence Therapeutics
16.3.16. Cenix BioScience
16.3.17. Sirnaomics
16.3.18. CureVac AG

17. Primary Key Insights
  • INQUIRE BEFORE BUYING